Head-to-head evidence
CT-996 vs VCT220
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
CT-996
Developed by Roche
NCT07081958 · Phase 2 · completed
The study randomized 352 participants to placebo or one of seven RO7795081 dosing regimens, with participants and investigators blinded. Its primary endpoint was the clinical measure of percent change in body weight at Week 30, but no results or statistical comparison have been posted, so the endpoint cannot yet be classified as met or missed.
Next expected readout: December 2026 · NCT06982131 (registry estimate)
VCT220
Developed by Ji Xing Pharmaceuticals (CORXEL) under a licence from Vincentage Pharma
NCT06569355 · Phase 2 · completed
This Phase 2 trial randomly assigned 250 people with obesity or overweight to one of several VCT220 doses or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was percentage change in body weight at week 16. Weight fell by between 5.8% and 9.7% across the VCT220 dose groups against 1.6% on placebo, with reductions of 9.7% and 9.4% at the two 160 mg schedules (p of 0.001 or lower).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CT-996's landscape · VCT220's landscape